Cognitive and behavioral assessment in Parkinson’s disease

References

• Obeso JA, Stamelou M, Goetz CG, et al. Past, present, and future of Parkinson’s disease: a special essay on the 200th Anniversary of the Shaking Palsy. Mov Disord. 2017;32(9):1264–1310.
   PubMed Web of Science ®Google Scholar
• Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30(12):1591–1601.
   PubMed Web of Science ®Google Scholar
• Duncan GW, Khoo TK, Yarnall AJ, et al. Health-related quality of life in early Parkinson’s disease: the impact of nonmotor symptoms. Mov Disord. 2014;29(2):195–202.
   PubMed Web of Science ®Google Scholar
• Gratwicke J, Jahanshahi M, Foltynie T. Parkinson’s disease dementia: a neural networks perspective. Brain. 2015;138(Pt 6):1454–1476.
   PubMed Web of Science ®Google Scholar
• Kulisevsky J, Pagonabarraga J, Pascual-Sedano B, et al. Prevalence and correlates of neuropsychiatric symptoms in Parkinson’s disease without dementia. Mov Disord. 2008;23(13):1889–1896.
   PubMed Web of Science ®Google Scholar
• Kulisevsky J, Pagonabarraga J. Cognitive impairment in Parkinson’s disease: tools for diagnosis and assessment. Mov Disord. 2009;24(8):1103–1110.
   PubMed Web of Science ®Google Scholar
• Litvan I, Aarsland D, Adler CH, et al. MDS Task Force on mild cognitive impairment in Parkinson’s disease: critical review of PD-MCI. Mov Disord. 2011;26(10):1814–1824.
   PubMed Web of Science ®Google Scholar
• Aarsland D, Bronnick K, Alves G, et al. The spectrum of neuropsychiatric symptoms in patients with early untreated Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2009;80(8):928–930.
   PubMed Web of Science ®Google Scholar
• Weintraub D, Simuni T, Caspell-Garcia C, et al. Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson’s disease. Mov Disord. 2015;30(7):919–927.
   PubMed Web of Science ®Google Scholar
• Litvan I, Goldman JG, Troster AI, et al. Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: movement disorder society task force guidelines. Mov Disord. 2012;27(3):349–356.
   PubMed Web of Science ®Google Scholar
• Skorvanek M, Goldman JG, Jahanshahi M, et al. Global scales for cognitive screening in Parkinson’s disease: critique and recommendations. Mov Disord. 2018;33(2):208–218.
   PubMed Web of Science ®Google Scholar
• Aarsland D, Andersen K, Larsen JP, et al. Risk of dementia in Parkinson’s disease: a community-based, prospective study. Neurology. 2001;56(6):730–736.
   PubMed Web of Science ®Google Scholar
• Hely MA, Reid WG, Adena MA, et al. The sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord. 2008;23(6):837–844.
   PubMed Web of Science ®Google Scholar
• Muslimovic D, Post B, Speelman JD, et al. Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology. 2005;65(8):1239–1245.
   PubMed Web of Science ®Google Scholar
• Williams-Gray CH, Evans JR, Goris A, et al. The distinct cognitive syndromes of Parkinson’s disease: 5 year follow-up of the CamPaIGN cohort. Brain. 2009;132(Pt11):2958–2969.
   PubMed Web of Science ®Google Scholar
• Chahine LM, Weintraub D, Hawkins KA, et al. Cognition in individuals at risk for Parkinson’s: Parkinson associated risk syndrome (PARS) study findings. Mov Disord. 2016;31(1):86–94.
   PubMed Web of Science ®Google Scholar
• Carbon M, Ma Y, Barnes A, et al. Caudate nucleus: influence of dopaminergic input on sequence learning and brain activation in Parkinsonism. NeuroImage. 2004;21(4):1497–1507.
   PubMed Web of Science ®Google Scholar
• Aarsland D, Andersen K, Larsen JP, et al. The rate of cognitive decline in Parkinson disease. Arch Neurol. 2004;61(12):1906–1911.
   PubMedGoogle Scholar
• Pagonabarraga J, Kulisevsky J, Llebaria G, et al. Parkinson’s disease-cognitive rating scale: a new cognitive scale specific for Parkinson’s disease. Mov Disord. 2008;23(7):998–1005.
   PubMed Web of Science ®Google Scholar
• Hilker R, Thomas AV, Klein JC, et al. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology. 2005;65(11):1716–1722.
   PubMed Web of Science ®Google Scholar
• Sampedro F, Marin-Lahoz J, Martinez-Horta S, et al. Dopaminergic degeneration induces early posterior cortical thinning in Parkinson’s disease. Neurobiol Dis. 2018;124:29–35.
   PubMed Web of Science ®Google Scholar
• Pagonabarraga J, Corcuera-Solano I, Vives-Gilabert Y, et al. Pattern of regional cortical thinning associated with cognitive deterioration in Parkinson’s disease. PloS One. 2013;8(1):e54980.
   PubMed Web of Science ®Google Scholar
• Cools R, Stefanova E, Barker RA, et al. Dopaminergic modulation of high-level cognition in Parkinson’s disease: the role of the prefrontal cortex revealed by PET. Brain. 2002;125(Pt 3):584–594.
   PubMed Web of Science ®Google Scholar
• Kulisevsky J, Avila A, Barbanoj M, et al. Acute effects of levodopa on neuropsychological performance in stable and fluctuating Parkinson’s disease patients at different levodopa plasma levels. Brain. 1996;119(Pt 6):2121–2132.
   PubMed Web of Science ®Google Scholar
• Kulisevsky J, Garcia-Sanchez C, Berthier ML, et al. Chronic effects of dopaminergic replacement on cognitive function in Parkinson’s disease: a two-year follow-up study of previously untreated patients. Mov Disord. 2000;15(4):613–626.
   PubMed Web of Science ®Google Scholar
• Rowe JB, Hughes L, Ghosh BC, et al. Parkinson’s disease and dopaminergic therapy–differential effects on movement, reward and cognition. Brain. 2008;131(Pt 8):2094–2105.
   PubMed Web of Science ®Google Scholar
• Gotham AM, Brown RG, Marsden CD. ‘Frontal’ cognitive function in patients with Parkinson’s disease ‘on’ and ‘off’ levodopa. Brain. 1988;111(Pt 2):299–321.
   PubMed Web of Science ®Google Scholar
• Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56(3):303–308.
   PubMed Web of Science ®Google Scholar
• Pedersen KF, Larsen JP, Tysnes OB, et al. Prognosis of mild cognitive impairment in early Parkinson disease: the norwegian parkwest study. JAMA Neurol. 2013;70(5):580–586.
   PubMed Web of Science ®Google Scholar
• Goldman JG, Holden S, Bernard B, et al. Defining optimal cutoff scores for cognitive impairment using movement disorder society task force criteria for mild cognitive impairment in Parkinson’s disease. Mov Disord. 2013;28(14):1972–1979.
   PubMed Web of Science ®Google Scholar
• Goldman JG, Holden S, Ouyang B, et al. Diagnosing PD-MCI by MDS task force criteria: how many and which neuropsychological tests? Mov Disord. 2015;30(3):402–406.
   PubMed Web of Science ®Google Scholar
• Matteau E, Dupre N, Langlois M, et al. Clinical validity of the Mattis dementia rating scale-2 in Parkinson disease with MCI and dementia. J Geriatr Psychiatry Neurol. 2012;25(2):100–106.
   PubMed Web of Science ®Google Scholar
• Dalrymple-Alford JC, MacAskill MR, Nakas CT, et al. The MoCA: well-suited screen for cognitive impairment in Parkinson disease. Neurology. 2010;75(19):1717–1725.
   PubMed Web of Science ®Google Scholar
• Fernandez de Bobadilla R, Pagonabarraga J, Martinez-Horta S, et al. Parkinson’s disease-cognitive rating scale: psychometrics for mild cognitive impairment. Mov Disord. 2013;28(10):1376–1383.
   PubMed Web of Science ®Google Scholar
• Marras C, Troster AI, Kulisevsky J, et al. The tools of the trade: a state of the art “how to assess cognition” in the patient with Parkinson’s disease. Mov Disord. 2014;29(5):584–596.
   PubMed Web of Science ®Google Scholar
• Kulisevsky J, Fernandez de Bobadilla R, Pagonabarraga J, et al. Measuring functional impact of cognitive impairment: validation of the Parkinson’s disease cognitive functional rating scale. Parkinsonism Relat Disord. 2013;19(9):812–817.
   PubMed Web of Science ®Google Scholar
• Brennan L, Siderowf A, Rubright JD, et al. Development and initial testing of the penn Parkinson’s daily activities questionnaire. Mov Disord. 2016;31(1):126–134.
   PubMed Web of Science ®Google Scholar
• Brennan L, Siderowf A, Rubright JD, et al. The penn Parkinson’s daily activities questionnaire-15: psychometric properties of a brief assessment of cognitive instrumental activities of daily living in Parkinson’s disease. Parkinsonism Relat Disord. 2016;25:21–26.
   PubMed Web of Science ®Google Scholar
• Aarsland D, Andersen K, Larsen JP, et al. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol. 2003;60(3):387–392.
   PubMedGoogle Scholar
• Aarsland D, Bronnick K, Williams-Gray C, et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology. 2010;75(12):1062–1069.
   PubMed Web of Science ®Google Scholar
• Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord. 2007;22(12):1689–1707. quiz 1837.
   PubMed Web of Science ®Google Scholar
• Hall H, Reyes S, Landeck N, et al. Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinson’s disease. Brain. 2014;137(Pt 9):2493–2508.
   PubMed Web of Science ®Google Scholar
• Seto-Salvia N, Pagonabarraga J, Houlden H, et al. Glucocerebrosidase mutations confer a greater risk of dementia during Parkinson’s disease course. Mov Disord. 2012;27(3):393–399.
   PubMed Web of Science ®Google Scholar
• Sampedro F, Marin-Lahoz J, Martinez-Horta S, et al. early gray matter volume loss in MAPT H1H1 de novo PD patients: a possible association with cognitive decline. Front Neurol. 2018;9:394.
   PubMed Web of Science ®Google Scholar
• Seto-Salvia N, Clarimon J, Pagonabarraga J, et al. Dementia risk in Parkinson disease: disentangling the role of MAPT haplotypes. Arch Neurol. 2011;68(3):359–364.
   PubMedGoogle Scholar
• O’Sullivan SS, Williams DR, Gallagher DA, et al. Nonmotor symptoms as presenting complaints in Parkinson’s disease: a clinicopathological study. Mov Disord. 2008;23(1):101–106.
   PubMed Web of Science ®Google Scholar
• Poewe W, Gauthier S, Aarsland D, et al. Diagnosis and management of Parkinson’s disease dementia. Int J Clin Pract. 2008;62(10):1581–1587.
   PubMed Web of Science ®Google Scholar
• Dubois B, Burn D, Goetz C, et al. Diagnostic procedures for Parkinson’s disease dementia: recommendations from the movement disorder society task force. Mov Disord. 2007;22(16):2314–2324.
   PubMed Web of Science ®Google Scholar
• Leiknes I, Tysnes OB, Aarsland D, et al. Caregiver distress associated with neuropsychiatric problems in patients with early Parkinson’s disease: the Norwegian ParkWest study. Acta Neurol Scand. 2010;122(6):418–424.
   PubMed Web of Science ®Google Scholar
• Dujardin K, Sockeel P, Delliaux M, et al. Apathy may herald cognitive decline and dementia in Parkinson’s disease. Mov Disord. 2009;24(16):2391–2397.
   PubMed Web of Science ®Google Scholar
• Frisina PG, Borod JC, Foldi NS, et al. Depression in Parkinson’s disease: health risks, etiology, and treatment options. Neuropsychiatr Dis Treat. 2008;4(1):81–91.
   PubMedGoogle Scholar
• Fenelon G, Mahieux F, Huon R, et al. Hallucinations in Parkinson’s disease: prevalence, phenomenology and risk factors. Brain. 2000;123(Pt 4):733–745.
   PubMed Web of Science ®Google Scholar
• Weintraub D, Stern MB. Psychiatric complications in Parkinson disease. Am J Geriatric Psychiatry. 2005;13(10):844–851.
   PubMed Web of Science ®Google Scholar
• Ravina B, Camicioli R, Como PG, et al. The impact of depressive symptoms in early Parkinson disease. Neurology. 2007;69(4):342–347.
   PubMed Web of Science ®Google Scholar
• Broen MP, Narayen NE, Kuijf ML, et al. Prevalence of anxiety in Parkinson’s disease: a systematic review and meta-analysis. Mov Disord. 2016;31(8):1125–1133.
   PubMed Web of Science ®Google Scholar
• Kulisevsky J, Pascual-Sedano B, Barbanoj M, et al. Acute effects of immediate and controlled-release levodopa on mood in Parkinson’s disease: a double-blind study. Mov Disord. 2007;22(1):62–67.
   PubMed Web of Science ®Google Scholar
• Bower JH, Grossardt BR, Maraganore DM, et al. Anxious personality predicts an increased risk of Parkinson’s disease. Mov Disord. 2010;25(13):2105–2113.
   PubMed Web of Science ®Google Scholar
• Torbey E, Pachana NA, Dissanayaka NN. Depression rating scales in Parkinson’s disease: a critical review updating recent literature. J Affect Disord. 2015;184:216–224.
   PubMed Web of Science ®Google Scholar
• Dissanayaka NN, Torbey E, Pachana NA. Anxiety rating scales in Parkinson’s disease: a critical review updating recent literature. Int Psychogeriatr. 2015;27(11):1777–1784.
   PubMed Web of Science ®Google Scholar
• Pagonabarraga J, Kulisevsky J, Strafella AP, et al. Apathy in Parkinson’s disease: clinical features, neural substrates, diagnosis, and treatment. Lancet Neurol. 2015;14(5):518–531.
   PubMed Web of Science ®Google Scholar
• Robert PH, Clairet S, Benoit M, et al. The apathy inventory: assessment of apathy and awareness in Alzheimer’s disease, Parkinson’s disease and mild cognitive impairment. Int J Geriatr Psychiatry. 2002;17(12):1099–1105.
   PubMed Web of Science ®Google Scholar
• Martinez-Horta S, Riba J, de Bobadilla RF, et al. Apathy in Parkinson’s disease: neurophysiological evidence of impaired incentive processing. J Neurosci. 2014;34(17):5918–5926.
   PubMed Web of Science ®Google Scholar
• Benito-Leon J, Cubo E, Coronell C, et al. Impact of apathy on health-related quality of life in recently diagnosed Parkinson’s disease: the ANIMO study. Mov Disord. 2012;27(2):211–218.
   PubMed Web of Science ®Google Scholar
• Martinez-Horta S, Sampedro F, Pagonabarraga J, et al. Non-demented Parkinson’s disease patients with apathy show decreased grey matter volume in key executive and reward-related nodes. Brain Imaging Behav. 2017;11(5):1334–1342.
   PubMed Web of Science ®Google Scholar
• Martinez-Horta S, Pagonabarraga J, Fernandez de Bobadilla R, et al. Apathy in Parkinson’s disease: more than just executive dysfunction. J Int Neuropsychol Soc. 2013;19(5):571–582.
   PubMed Web of Science ®Google Scholar
• Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010;67(5):589–595.
   PubMed Web of Science ®Google Scholar
• Weintraub D, David AS, Evans AH, et al. Clinical spectrum of impulse control disorders in Parkinson’s disease. Mov Disord. 2015;30(2):121–127.
   PubMed Web of Science ®Google Scholar
• Leentjens AF, Dujardin K, Marsh L, et al. Apathy and anhedonia rating scales in Parkinson’s disease: critique and recommendations. Mov Disord. 2008;23(14):2004–2014.
   PubMed Web of Science ®Google Scholar
• Weintraub D, Mamikonyan E, Papay K, et al. Questionnaire for impulsive-compulsive disorders in Parkinson’s disease-rating scale. Mov Disord. 2012;27(2):242–247.
   PubMed Web of Science ®Google Scholar
• Weintraub D, Hoops S, Shea JA, et al. Validation of the questionnaire for impulsive-compulsive disorders in Parkinson’s disease. Mov Disord. 2009;24(10):1461–1467.
   PubMed Web of Science ®Google Scholar
• Pereira B, Llorca PM, Durif F, et al. Screening hypersexuality in Parkinson’s disease in everyday practice. Parkinsonism Relat Disord. 2013;19(2):242–246.
   PubMed Web of Science ®Google Scholar
• Kulisevsky J, Roldan E. Hallucinations and sleep disturbances in Parkinson’s disease. Neurology. 2004;63(8 Suppl 3):S28–30.
   PubMed Web of Science ®Google Scholar
• Galvin JE, Pollack J, Morris JC. Clinical phenotype of Parkinson disease dementia. Neurology. 2006;67(9):1605–1611.
   PubMed Web of Science ®Google Scholar
• Pagonabarraga J, Martinez-Horta S, Fernandez de Bobadilla R, et al. Minor hallucinations occur in drug-naive Parkinson’s disease patients, even from the premotor phase. Mov Disord. 2016;31(1):45–52.
   PubMed Web of Science ®Google Scholar
• Forsaa EB, Larsen JP, Wentzel-Larsen T, et al. A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol. 2010;67(8):996–1001.
   PubMedGoogle Scholar
• Mosimann UP, Rowan EN, Partington CE, et al. Characteristics of visual hallucinations in Parkinson disease dementia and dementia with lewy bodies. Am J Geriatric Psychiatry. 2006;14(2):153–160.
   PubMed Web of Science ®Google Scholar
• Brandstaedter D, Spieker S, Ulm G, et al. Development and evaluation of the Parkinson psychosis questionnaire a screening-instrument for the early diagnosis of drug-induced psychosis in Parkinson’s disease. J Neurol. 2005;252(9):1060–1066.
   PubMed Web of Science ®Google Scholar
• Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44(12):2308–2314.
   PubMed Web of Science ®Google Scholar
• Goetz CG, Leurgans S, Pappert EJ, et al. Prospective longitudinal assessment of hallucinations in Parkinson’s disease. Neurology. 2001;57(11):2078–2082.
   PubMed Web of Science ®Google Scholar